We can’t show the full text here under this license. Use the link below to read it at the source.
Effects of GLP‐1 Receptor Agonists in Alcohol Use Disorder
Effects of GLP-1 Receptor Agonists on Alcohol Use Disorder
AI simplified
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may offer a novel treatment for (AUD).
- GLP-1 is a peptide that helps regulate blood sugar levels and feelings of fullness, produced in the intestines and brain.
- Preclinical studies and case reports suggest potential benefits of GLP-1RAs for individuals with AUD.
- Register-based cohort studies and brain-imaging data support the involvement of GLP-1RAs in AUD treatment strategies.
- Ongoing clinical trials are assessing the effects of the GLP-1RA semaglutide on AUD.
AI simplified
Key numbers
280 million
280 million
Estimated number of people suffering from worldwide.
29%
29%
Cumulative mortality rate after first hospital contact due to alcohol issues.
45%–90%
45%–90%
Estimated percentage of patients who relapse within the first 3 years of treatment.